Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 14/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | S100A4 | P26447 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29739895 | 1.00 | CYP19A1 (0.49) | CYP19A1ALDH1A1KDM4EHTTS100A4 | |
| SCHEMBL12491825 | 0.88 | CYP19A1 (0.52) | CYP19A1ALDH1A1KDM4EHTTS100A4 | |
| SCHEMBL20225763 | 0.83 | TSHR (0.53) | CYP19A1ALDH1A1KDM4EHTTMAPT | |
| SCHEMBL1844442 | 0.82 | MAPT (0.47) | ALDH1A1KDM4EHTTS100A4TRPV1 | |
| SCHEMBL26119927 | 0.81 | TXNRD1 (0.39) | CYP19A1ALDH1A1KDM4EHTTS100A4 | |
| SCHEMBL29686475 | 0.81 | TXNRD1 (0.39) | CYP19A1ALDH1A1KDM4EHTTS100A4 | |
| SCHEMBL3617121 | 0.81 | CYP19A1 (0.50) | CYP19A1ALDH1A1KDM4EHTT | |
| SCHEMBL29686179 | 0.81 | TSHR (0.50) | CYP19A1ALDH1A1KDM4EHTTMAPT | |
| SCHEMBL26118896 | 0.81 | TSHR (0.50) | CYP19A1ALDH1A1KDM4EHTTMAPT | |
| SCHEMBL23933066 | 0.79 | POLB (0.55) | CYP19A1ALDH1A1HTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3848370-B1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICALS CO (JP) | 2025-05-07 | — | — | EP | disclosed |
| US-20240101548-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD (CN) | 2024-03-28 | — | — | US | disclosed |
| EP-4257587-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| EP-4206196-A1 | PYRIMIDINE SUBSTITUTED DERIVATIVES AS TYK2 INHIBITORS | Almirall S.A. (ES) | 2023-07-05 | — | — | EP | disclosed |
| CN-116283954-A | Hydroxamate compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20230159556-A1 | NOVEL PROTEIN KINASE INHIBITORS | TENOVA PHARMACEUTICALS INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159556-A1 | NOVEL PROTEIN KINASE INHIBITORS | TENOVA PHARMACEUTICALS INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230159556-A1 | NOVEL PROTEIN KINASE INHIBITORS | TENOVA PHARMACEUTICALS INC. | 2023-05-25 | — | — | US | disclosed |
| CN-114901656-B | Hydroximic acid ester compound, preparation method and application thereof | 深圳微芯生物科技股份有限公司 | 2023-04-07 | — | — | CN | disclosed |
| CN-115448916-A | TYK2 inhibitor and application thereof | 林伯士拉克许米公司 | 2022-12-09 | — | — | CN | disclosed |
| US-20190284194-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-09-19 | — | — | US | disclosed |
| EP-3528816-A1 | TYK2 INHIBITORS AND USES THEREOF | Nimbus Lakshmi, Inc. (US) | 2019-08-28 | — | — | EP | disclosed |
| EP-3526222-A1 | TYK2 INHIBITORS AND USES THEREOF | Nimbus Lakshmi, Inc. (US) | 2019-08-21 | — | — | EP | disclosed |
| US-10323036-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2019-06-18 | — | — | US | disclosed |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | US | disclosed |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-07 | — | — | US | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-05-17 | — | — | US | disclosed |
| WO-2018075937-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
| WO-2018071794-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101548-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | TYK2, WEE2, WEE1 | CYP19A1 1198/4885ALDH1A1 3779/4885KDM4E 1202/4885 |
| US-10323036-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | CYP19A1 2724/4885ALDH1A1 4827/4885KDM4E 391/4885 |
| US-20180134700-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CYP19A1 2724/4885ALDH1A1 4827/4885KDM4E 391/4885 |
| US-20230159556-A1 | NOVEL PROTEIN KINASE INHIBITORS | ERBB2, ALK, ERBB3 | CYP19A1 4431/4885ALDH1A1 4050/4885KDM4E 2096/4885 |
| US-20190284194-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CYP19A1 2724/4885ALDH1A1 4827/4885KDM4E 391/4885 |
| US-20180155349-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | CYP19A1 2724/4885ALDH1A1 4827/4885KDM4E 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.